X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
1. Asmanex
2. Asmanex Twisthaler
3. Elocon
4. Furoate Monohydrate, Mometasone
5. Furoate, Mometasone
6. Mometasone
7. Mometasone Furoate Monohydrate
8. Monohydrate, Mometasone Furoate
9. Nasonex
10. Rinelon
11. Sch 32088
12. Sch-32088
13. Sch32088
14. Twisthaler, Asmanex
1. 83919-23-7
2. Asmanex
3. Nasonex
4. Elocon
5. Monovo
6. Sch 32088
7. Mometasone 17-furoate
8. Sinuva
9. Mometasone Furoate Anhydrous
10. Sch32088
11. Sch-32088
12. Nsc-746171
13. Chembl1161
14. Lyr210
15. (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl Furan-2-carboxylate
16. [(8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate
17. Chebi:47564
18. Lyr-210
19. 04201gdn4r
20. Nsc-760077
21. (11beta,16alpha)-9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
22. Danitin
23. Ecural
24. Elomet
25. Dsstox_cid_3333
26. Asmanex Twisthaler
27. Dsstox_rid_76981
28. Dsstox_gsid_23333
29. (9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
30. 9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
31. Elocone
32. Flumeta
33. Nosorex
34. Rimelon
35. Ovixan
36. Asmanex Hfa
37. Mometasone Fuorate
38. Mof
39. Unii-04201gdn4r
40. Mometasone-furoate
41. Ncgc00016950-01
42. Prestwick_924
43. Asmanex (tn)
44. Mometasone Furoate [usan:usp:jan]
45. Cas-83919-23-7
46. Elocon (tn)
47. Las 41002
48. Brn 4340538
49. Prestwick0_000572
50. Prestwick1_000572
51. Prestwick2_000572
52. Prestwick3_000572
53. Mometasone Furancarboxylate
54. Schembl4568
55. Bspbio_000384
56. Mometasone 17-(2-furoate)
57. Mls002153879
58. Spbio_002603
59. Mometasone Furoate (jan/usp)
60. Bpbio1_000424
61. Mometasone Furoate [mi]
62. Dtxsid4023333
63. Mometasone Furoate [jan]
64. Mometasone Furoate [usan]
65. Hms1569d06
66. Hms2096d06
67. Hms2235i14
68. Hms3713d06
69. Mometasone Furoate [vandf]
70. Mometasone Furoate [mart.]
71. Mometasone Furoate [usp-rs]
72. Mometasone Furoate [who-dd]
73. Zinc3938677
74. Tox21_110705
75. Ac-941
76. Bdbm50148733
77. Mfcd00866003
78. Nsc746171
79. S1987
80. Mometasone Furoate, >=98% (hplc)
81. Akos015994732
82. Tox21_110705_1
83. Ccg-220572
84. Db14512
85. Ks-1275
86. Mometasone Furoate [green Book]
87. Nsc 746171
88. Nsc 760077
89. 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
90. Mometasone Furoate [orange Book]
91. Mometasone Furoate [ep Monograph]
92. Ncgc00179578-01
93. Ncgc00179578-03
94. Ncgc00179578-04
95. (11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
96. Dulera Component Mometasone Furoate
97. Hy-13693
98. Mometasone Furoate [usp Monograph]
99. Smr001233233
100. M2354
101. Mometasone Furoate Component Of Dulera
102. C07817
103. D00690
104. Mometasone Furoate 1000 Microg/ml In Methanol
105. 919m237
106. A840685
107. Mometasone Furoate 100 Microg/ml In Acetonitrile
108. Sr-01000841209
109. Lyr-220 Active Component Mometasone Furoate
110. Q-101380
111. Q1044248
112. Sr-01000841209-2
113. Brd-k60640630-001-03-7
114. Brd-k60640630-001-11-0
115. Mometasone Furoate, European Pharmacopoeia (ep) Reference Standard
116. Mometasone Furoate, United States Pharmacopeia (usp) Reference Standard
117. 11?,16?)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
118. Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material
119. (11.beta.,16.alpha.)-9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
120. [(8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate;mometasone Furoate
121. [(9r,10s,11s,13s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate
122. 9,21-dichloro-11.beta.,17-dihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
123. Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-
124. Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)
125. Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-
| Molecular Weight | 521.4 g/mol |
|---|---|
| Molecular Formula | C27H30Cl2O6 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 520.1419441 g/mol |
| Monoisotopic Mass | 520.1419441 g/mol |
| Topological Polar Surface Area | 93.8 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 1020 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Elocon |
| Drug Label | ELOCON (mometasone furoate) Ointment, 0.1% contains mometasone furoate for topical use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.Chemically, mometasone furoate is 9,21-dichloro-11,17-dihydroxy-16-methylpr... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 2 of 6 | |
|---|---|
| Drug Name | Mometasone furoate |
| PubMed Health | Mometasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong |
| Drug Label | Mometasone furoate, the active component of the ASMANEX TWISTHALER product, is a corticosteroid with the chemical name 9,21-dichloro-11(Beta),17-dihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) and the following chemical structure... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Ointment; Cream; Lotion |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Taro; Glenmark Generics; Fougera Pharms; Perrigo; Perrigo New York; Tolmar; G And W Labs |
| 3 of 6 | |
|---|---|
| Drug Name | Nasonex |
| Drug Label | Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione17-(2 furoate) monohydrate, an... |
| Active Ingredient | Mometasone furoate monohydrate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | eq 0.05mg base/spray |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 4 of 6 | |
|---|---|
| Drug Name | Elocon |
| Drug Label | ELOCON (mometasone furoate) Ointment, 0.1% contains mometasone furoate for topical use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.Chemically, mometasone furoate is 9,21-dichloro-11,17-dihydroxy-16-methylpr... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 5 of 6 | |
|---|---|
| Drug Name | Mometasone furoate |
| PubMed Health | Mometasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong |
| Drug Label | Mometasone furoate, the active component of the ASMANEX TWISTHALER product, is a corticosteroid with the chemical name 9,21-dichloro-11(Beta),17-dihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) and the following chemical structure... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Ointment; Cream; Lotion |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Taro; Glenmark Generics; Fougera Pharms; Perrigo; Perrigo New York; Tolmar; G And W Labs |
| 6 of 6 | |
|---|---|
| Drug Name | Nasonex |
| Drug Label | Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione17-(2 furoate) monohydrate, an... |
| Active Ingredient | Mometasone furoate monohydrate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | eq 0.05mg base/spray |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients 4 years. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients 2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients 2 years, treating nasal polyps in patients 18 years, and prophylaxis of seasonal allergic rhinitis in patients 12 years. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients 2 years.
FDA Label
Seasonal and perennial allergic rhinitis
Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of [dexamethasone]. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammation.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Absorption
The mean time to peak concentration is 1.0 to 2.5 hours. Bioavailability has been reported as <1% but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%. The 0.1% ointment may have a bioavailability of 0.7%.
Route of Elimination
For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine.
Volume of Distribution
Steady state volume of distribution of 152L.
Clearance
The clearance rate of mometasone furoate is not readily available, though it may be close to 90L/h.
Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolites. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate.
The terminal half life of an inhaled dose is approximately 5 hours though it has been reported as 5.8 hours by other sources.
In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes. There is also evidence of inhibition of histamine, leukotrienes, and cytokines. Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of [dexamethasone]. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5). Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB).
Market Place
